Company / Depreciation & Amortization
IGC Pharma, Inc. Depreciation & Amortization History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Depreciation & Amortization
$618.0K
FY2025
5-year range
$144.0K / $657.0K
FY2021-FY2025
Trend
-5.9%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $651,000 to $618,000 over the past 2 years.
Based on SEC 10-K filings.
$618,000 in FY2025 with a 5-year CAGR of +60.0%.
Improved from $651,000 to $618,000 over the past 2 years.
Depreciation & Amortization over time
Growth rates
- 3-Year CAGR
- +8.9%
- 5-Year CAGR
- +60.0%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +60.0%, indicating consistent growth.
- In FY2025, depreciation & amortization decreased 5.9% year-over-year.
- Peak depreciation & amortization was recorded in FY2016.
- Lowest depreciation & amortization in the period was in FY2019.
Company context
Key Data Points
- Altman Z-Score -13.04 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Depreciation & AmortizationValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $618.0K | -5.9% |
| FY2024 | $657.0K | +0.9% |
| FY2023 | $651.0K | +36.2% |
| FY2022 | $478.0K | +231.9% |
| FY2021 | $144.0K | +144.1% |
| FY2020 | $59.0K | +210.5% |
| FY2019 | $19.0K | -95.2% |
| FY2018 | $396.3K | -45.6% |
| FY2017 | $728.7K | -6.8% |
| FY2016 | $781.5K | +9.7% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026